Navigation Links
Flu Vaccine Via Skin Patch Shows Promise in Mice
Date:7/19/2010

By Jenifer Goodwin
HealthDay Reporter

SUNDAY, July 18 (HealthDay News) -- Wouldn't it be nice if you could get the flu vaccine through a stick-on skin patch instead of a shot?

Experiments in mice show that using skin patches containing tiny, painless "microneedles" to deliver the influenza vaccine may someday be a viable alternative to traditional shots.

The microneedles -- less than 1 millimeter in length, or about half the thickness of a nickel turned on its side -- dissolve into the skin and are small enough that they don't draw blood or cause pain, researchers said.

Better yet, if the patches are found to work in humans, getting an immunization may be as simple as stopping by the pharmacy, picking up your patch and slapping it on.

"For vaccination, it could be a game changer," said lead study author Sean Sullivan, who did the research when he was a doctoral student at Emory University and Georgia Institute of Technology. "There are so many little annoyances with the [standard] vaccination process that could go away."

The study is published in the July 18 online issue of Nature Medicine.

Experts agreed the findings were promising. "This is a tremendous advancement in the technology," said Rick Bright, scientific director of the Influenza Vaccine Project at PATH in Washington, D.C.

Because the patch appeared to work using less vaccine than in a typical shot, the discovery has the potential to reduce the amount of vaccine that needs to be produced, which could alleviate shortages in case of pandemic flu, Bright added.

Dr. Paul A. Offit, director of the Vaccine Education Center and chief of infectious diseases at Children's Hospital of Philadelphia, also called the technology a "breakthrough."

However, "the caveat is, this needs to be extended to humans," Offit said. "It's not uncommon for vaccines or vaccine delivery systems to look very promising in experimental animals, then fail in humans. But there is every reason to believe this kind of technology could be applicable to children and adults."

Other through-the-skin vaccine delivery attempts have failed to produce enough an immune response, in part because the thickness and water content of people's skin varies by age, race and ethnicity far more than a mouse skin. However, the new technology appears to overcome that by delivering the vaccine slightly deeper, Bright added.

The next step is getting funding to begin clinical trials, which researchers said they hope to being in the next couple of years.

In a normal flu shot, vaccine is delivered into the muscle. With the patch, the vaccine is encased in water-soluble polymer needles on the patch. When placed on the skin, the needles dissolve almost immediately, delivering vaccine into the skin and provoking a localize immune response.

From there, the immune cells travel via the lymph system through the body, prompting a systemic, or whole body, immunization -- at least in mice.

The mice who had the patches showed a robust immune response to the vaccine. In addition, the vaccinated mice easily survived what would have otherwise been a lethal dose of the flu.

In addition to its other benefits, a skin patch vaccine would not have to be refrigerated, a problem in developing countries, and there would be fewer medical waste issues, such as disposing of used syringes, researchers said.

More information

The U.S. Centers for Disease Control and Prevention has more on the flu.

SOURCES: Sean Sullivan, Ph.D., Emory University and Georgia Institute of Technology, Atlanta, Ga.; Rick Bright, Ph.D, scientific director, Influenza Vaccine Project, PATH, Washington, D.C; Paul A. Offit, M.D., director, Vaccine Education Center and chief of infectious diseases, Children's Hospital of Philadelphia, Philadelphia, Pa.; Nature Medicine, July 18, 2010.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Future HIV vaccines: If we build it, will they come?
2. Sex With Recent Smallpox Vaccine Recipient Can Lead to Illness
3. Combination MMRV vaccine linked with 2-fold risk of seizures
4. H1N1 Flu Vaccine May Shield Against 1918 Strain
5. NIH-funded scientists find 2009 H1N1 pandemic influenza vaccine protects mice from 1918 flu virus
6. One-Third of U.S. Girls Get HPV Vaccine
7. One-third of young girls get HPV vaccine to prevent cervical cancer
8. Prostate Cancer Vaccine Shows Few Side Effects
9. Breast Cancer Vaccine Possible, Scientists Say
10. Vaccine hope for skin cancer sufferers
11. Mount Sinai researchers move closer to a universal influenza vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Flu Vaccine Via Skin Patch Shows Promise in Mice
(Date:3/29/2017)... , ... March 29, 2017 , ... During the last ... provide free screening colonoscopies to eligible individuals in the local community. , Colon ... but regular screenings can detect colon cancer while it is small, confined and easier ...
(Date:3/29/2017)... , ... March 29, 2017 , ... Full Contact K9, ... of Pet Protect Law that assists dog owners in creating legally-enforceable pet ... owners in taking the natural next step to protect their new companion. Says Evan ...
(Date:3/29/2017)... Petersburg, FL (PRWEB) , ... March 30, 2017 , ... ... called the "Spice of Life" or "Wonder Spice", it has been used for thousands ... use in the East," says Heshelow, author of " Turmeric: How to Use it ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wall Centre Dental ... new patients from Burnaby, BC. Patients in need of experienced orthodontics, laser dentistry, ... see the esteemed team at Wall Centre Dental. Drs. Parviz Roshan, Siamak Tehrani, ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... as it continues developing an ANSI-approved, consensus-based American National Standard for Good ... to publish the first ANSI-approved GMP standard for dietary supplements this spring, ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  The Global ... Japanese public-private partnership formed to battle infectious diseases ... totaling US$23 million* that could help deliver a ... of debilitating conditions. This latest ... Phase 3 clinical trial testing a pediatric formulation ...
(Date:3/29/2017)... TREE, Colo. , March 29, 2017  Zynex (OTCQB: ... manufacture and sale of non-invasive medical devices for pain ... today that it will host the Company,s 2016 full-year ... a.m. Eastern Time.) The Company expects to ... 31, 2017. ...
(Date:3/29/2017)... 29, 2017  Glenmark Pharmaceuticals, a global pharmaceutical ... an investigational fixed-dose combination of mometasone furoate (25 ... as a nasal spray being studied for the ... from a recently completed Phase 3 trial assessing ... therapy versus mometasone, olopatadine or placebo. ...
Breaking Medicine Technology: